Health-care companies were more or less flat as traders rotated into defensive sectors, hedging against the implications of rising interest rates.
Biogen will aim for 18% of the participants in the post-approval trial that regulators are requiring it to run of its Alzheimer's disease therapy Aduhelm to be Black or Latino, an attempt to correct course after these groups were underrepresented in a previous trial despite suffering high rates of Alzheimer's.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
01-27-22 1706ET
